Literature DB >> 26040165

[Subcutaneous immunoglobulin and support program: what level of interest of patients?].

A Bourdin, J Berger, A Früh, F Spertini, O Bugnon.   

Abstract

Two different routes of administration exist for the immunoglobulin therapy: intravenous (Ig IV - monthly administration in medical setting) and subcutaneous (Ig SC - weekly self-administration at home). According to the literature, efficacy and safety are similar,. but Ig SC could improve quality of life and treatment satisfaction. The Policlinique Médicale Universitaire of Lausanne has developed an interdisciplinary program for the long-term support of Ig SC patients. Moreover, it conducted an exploratory survey interviewing Ig IV patients about their interest for Ig SC: patients interested judged less favourably efficacy and/or tolerance of Ig IV and considered that Ig SC would improve their motivation for treatment and its impact on their private and professional life.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26040165

Source DB:  PubMed          Journal:  Rev Med Suisse        ISSN: 1660-9379


  4 in total

1.  Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.

Authors:  Clemence Perraudin; Aline Bourdin; Francois Spertini; Jérôme Berger; Olivier Bugnon
Journal:  J Clin Immunol       Date:  2016-05-02       Impact factor: 8.317

2.  II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.

Authors:  Ekaterini Simões Goudouris; Almerinda Maria do Rego Silva; Aluce Loureiro Ouricuri; Anete Sevciovic Grumach; Antonio Condino-Neto; Beatriz Tavares Costa-Carvalho; Carolina Cardoso Prando; Cristina Maria Kokron; Dewton de Moraes Vasconcelos; Fabíola Scancetti Tavares; Gesmar Rodrigues Silva Segundo; Irma Cecília Barreto; Mayra de Barros Dorna; Myrthes Anna Barros; Wilma Carvalho Neves Forte
Journal:  Einstein (Sao Paulo)       Date:  2017

Review 3.  Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management.

Authors:  Pere Soler-Palacín; Javier de Gracia; Luis Ignacio González-Granado; Carlos Martín; Carlos Rodríguez-Gallego; Silvia Sánchez-Ramón
Journal:  Respir Res       Date:  2018-11-12

4.  Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis.

Authors:  Clémence Perraudin; Aline Bourdin; Alex Vicino; Thierry Kuntzer; Olivier Bugnon; Jérôme Berger
Journal:  PLoS One       Date:  2020-11-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.